|08:30 - 09:30
||Session 5: Keynote lecture by Natalie Sims: “Diverse roles of osteocytes in controlling bone mass, composition and shape" (or an updated title along this topic)
|09:30 - 10:30
|10:30 - 12:00
Methodological/thematic interactive workshops (including coffee and drinks)
- "Getting mouse phenotypes right" (by Natalie Sims)
- “CrispR technology” (by Matthew Warman)
- “Mouse models of bone invasion by cancer” (by Claire Edwards)
|12:00 - 12:45
||Poster viewing and discussion
|12:45 - 13:45
|13:45 - 14:45
||Session 6: Keynote lecture by Seiji Fukumoto: “Kidney-‐bone communication” (or an updated title along this topic)
|14:45 - 15:45
|15:45 - 16:00
||Brugge city excursion and museum visit
Invited Keynote Speakers, mentoring the meeting
Lynda Bonewald, University of Missouri-Kansas City (Kansas City, USA)
Dr. Bonewald is the Vice Chancellor for Translational and Clinical Research, Curators’ Professor, Lee M. and William Lefkowitz Professor, Director, UMKC-CEMT, and Director, Bone Biology Research Program in the UMKC School of Dentistry, Department of Oral Biology. She has made many contributions to bone cell biology in respect of the effects of growth factors in bone, and in the last several years has led research that has revealed the importance of the osteocyte as a powerful regulatory cell of many functions in bone.
Claire Edwards, University of Oxford (Oxford, UK) Associate Professor
Claire Edwards obtained a first class honors degree and Ph.D. from the University of Sheffield, where she began her career in cancer-induced bone disease. Following postdoctoral studies at the University of Sheffield and the University of Oxford, she moved to the United States in 2004 to take up assistant professor positions at the University of Texas Health Science Center at San Antonio and subsequently at Vanderbilt University. Dr. Edwards is the recipient of multiple awards and fellowships, including most recently, the Iain T. Boyle Award from the European Calcified Tissue Society. Dr. Edwards has recently relocated her lab to the University of Oxford as a University Lecturer in Bone Oncology, with a joint appointment in NDORMS and the Nuffield Dept. of Surgical Sciences, and a fellowship at St. Edmund Hall. Her research interests are focused upon the pathogenesis of cancer-induced bone disease, including the contributions of the host bone marrow microenvironment and the role of obesity, adipocytes and adipokines.
Seiji Fukumoto, Tokushima University (Tokushima, Japan)
Dr. Fukumoto is a Project Professor of the Department of Nuclear Receptor Ligands and Vitamins Research, Fujii Memorial Institute of Medical Sciences, Tokushima University. He received his MD degree in 1982 and PhD degree in 1990 from the University of Tokyo. After receiving PhD degree, he spent a couple years in the laboratory headed by Prof. T.J. Martin in Melbourne. His areas of interest include homeostatic control and derangements of mineral metabolism, and pathogenesis and treatment of metabolic bone diseases. He has contributed to the cloning of FGF23, the development of assay for FGF23 and the clarification of mechanisms of actions of FGF23. He is now involved in the clinical, educational and research works in Tokushima University.
Fanxin Long, Washington University in St. Louis (St. Louis, USA)
Dr. Long completed his bachelor of science degree in cell biology from Peking University in Beijing, China. He then earned a master's degree in Molecular Biology from the University of California in Santa Barbara, California and a doctorate degree in Developmental Biology from Tufts University Medical School, in Boston, Massachusetts. Dr. Long previously served as an Assistant Professor of Medicine and Developmental Biology as well as an Associate Professor of Medicine at Washington University School of Medicine. Dr. Long currently serves as a Professor of Medicine and Developmental Biology in the department of Orthopaedic Surgery at Washington University School of Medicine. Dr. Long is generally interested in understanding the molecular underpinnings of cellular differentiation, focusing particularly on osteoblast differentiation in skeletal development and homeostasis. His research has revealed that developmental pathways such as governed by Hedgehog, Notch and Wnt signals play key yet distinct roles in controlling osteoblast differentiation. A major current focus of the Long lab is on the emerging role for cellular metabolism in bone formation and our understanding of the molecular control of osteoblast metabolism by Wnt and other signaling pathways.
Natalie Sims, St. Vincent's Institute of Medical Research (Melbourne, Australia)
Associate Professor Natalie Sims received her PhD from the University of Adelaide, Australia in 1995. She directs the Bone Cell Biology and Disease Unit at St. Vincent’s Institute and is a Principal Research Fellow at The University of Melbourne. Natalie is a board member of the Australian and New Zealand Bone and Mineral Society, the International Bone and Mineral Society, and the ASBMR, a Senior Editor of the journal Bone, and past Associate Editor of CTI. She received the ASBMR Fuller Albright Award (2010) and the IBMS Herbert A Fleisch Award (2013). Her work focuses on the paracrine control of osteoblast and osteoclast function, particularly by ephrin and IL-6 family cytokines, using genetically altered mouse models and in vitro systems.
Matthew Warman, Harvard Medical School (Boston, MA)
Dr. Matthew Warman, M.D. is the Harriet M. Peabody Professor of Orthopedic Surgery, Department of Genetics, Harvard Medical School, the Director of the Orthopaedic Research Laboratories at Boston Children’s Hospital, and Professor of Genetics at Harvard Medical School. Dr. Warman studied material science at Brown University and medicine at Cornell University Medical College. He completed an internship and residency in pediatrics at the Children’s Hospital in Washington D.C., and a fellowship in medical genetics at the Children’s Hospital in Boston. Following completion of his fellowship in 1989, he remained on staff as a clinical geneticist and also joined the laboratory of Dr. Bjorn Olsen at Harvard Medical School as a postdoctoral fellow. He subsequently joined the faculty at Case Western Reserve University School of Medicine. Dr. Warman is board certified in Pediatrics as well as in Clinical, Biochemical, and Molecular Genetics and maintains a strong clinical interest in these disciplines. Dr. Warman and his lab members are committed to identifying genetic causes of skeletal disease, to understanding how the responsible genes participate in the biologic processes of skeletal growth and homeostasis, and to using this knowledge to improve human health.